Bladder cancer is a heterogeneous malignancy and is responsible for approximately 3.2%
of new diagnoses of cancer per year (Sung et al., 2021). Fibroblast Growth Factor Receptors …

Bladder cancer is a highly prevalent disease and is associated with substantial morbidity,
mortality and cost. Environmental or occupational exposures to carcinogens, especially …

Mutational signature analysis is commonly performed in cancer genomic studies. Here, we
present SigProfilerExtractor, an automated tool for de novo extraction of mutational …

It has been 12 yr since the publication of the last World Health Organization (WHO)
classification of tumours of the prostate and bladder. During this time, significant new …

There is substantial heterogeneity among primary prostate cancers, evident in the spectrum
of molecular abnormalities and its variable clinical course. As part of The Cancer Genome …

Despite more than three decades of intensive effort, no effective pharmacological inhibitors
of the RAS oncoproteins have reached the clinic, prompting the widely held perception that …

Urothelial carcinoma of the bladder comprises two long-recognized disease entities with
distinct molecular features and clinical outcome. Low-grade non-muscle-invasive tumours …

FGFR signaling is deregulated in many human cancers, and FGFR is considered a valid
target in FGFR-deregulated tumors. Here, we examine the preclinical profile of futibatinib …

BACKGROUND Multicellular organisms depend on the precise orchestration of gene
expression to direct embryonic development and to maintain tissue homeostasis through …

Alterations in DNA repair pathways are common in tumors and can result in characteristic
mutational signatures; however, a specific mutational signature associated with somatic …